Economic value of Tislelizumab plus chemotherapy in advanced oesophageal squamous-cell carcinoma: a price-dependent analysis under uncertain comparator eligibility
To estimate conditional break-even acquisition prices for tislelizumab plus chemotherapy against existing immunotherapy comparators in advanced oesophageal squamous-cell carcinoma, examining comparative efficacy, comparator acquisition discounts and relative treatment exposure.
Authors
- İsmail Ersöz (ORCID: https://orcid.org/0009-0008-4474-3275)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-19
- DOI
- https://doi.org/10.5281/zenodo.24367330
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00